Abstract
Didemnin B (NSC-325319), a new depsipeptide isolated from a Caribbean tunicate, has been evaluated in a clinical phase I study. The drug was administered in a schedule of a 4 weekly intravenous injection in a six-weeks cycle. Fifty-three patients received 71 evaluable cycles in an escalated dose ranging from 0.4 mg/m2/week to 2.5 mg/m2/week. No hematological toxicity was demonstrated at any dose level. Without prophylactic antiemetics nausea and vomiting was dose limiting at 1.2 mg/m2/week. Due to the use of Cremophor EL as a solvent, hypersensitivity reactions occurred in 9 patients. These reactions occurred following prior exposure to the drug and were commonly seen at the 3rd dose. They were not dose related but became more frequent at 1.5 mg/m2/week necessitating prophylactic treatment with H1 and H2 receptor blocking agents. Non-hematological toxicities included mild diarrhea, mucositis, anorexia, headaches, and local phlebitis. The dose- limiting toxicity was generalized weakness which became severe and disabling in 3 of 6 patients treated at 2.5 mg/m2/week. No objective responses were documented in 39 patients with evaluable disease. The recommended dose for phase II studies was 2.3 mg/m2/week × 4 4 in a 6-weeks cycle given with prophylactic antiemetics and H1 and H2 receptor blocking agents.
Similar content being viewed by others
References
Reinhart KL, Gloer JB, Hughes RG, Renis HE, Mcgovern JP, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH: Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212:933-955, 1981
Clinical Brochure on didemnin B (NSC-325319). Prepared by the Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, June 1984
Jiang TL, Liu RH, Salmon SE: Antitumor activity of didemnin B in the human tumor stem cell assay. Cancer Chemother Pharmacol 11:1–4, 1984
Montgomery DW, Zukoski CF. Didemnin B: A new immunosuppressive cyclic peptide with potent activity in vitroand in vivo. Transplantation 40:49-56, 1985
Li LH, Timmins LG, Wallace TL, Krueger WC, Prairie MD, Im WB: Mechanism of action of didemnin B, a depsipeptide from the sea. Cancer Lett 23:279-288, 1984
Dorr FA, Kuhn JG, Phillips J, Von Hoff DD: Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide. Eur J Cancer Clin Oncol 24:1699-1706, 1988
Stewart JA, Low JB, Roberts JD, Blow A: A Phase I Clinical Trial of didemnin B. Cancer 68(12):2550-2554, 1991
Abbruzzese J, Ajani J, Blackburn R, Faintuch J, Patt Y, Levin B: Phase II Study of didemnin B in Advanced Colorectal Cancer. Proc Am Assoc Cancer Res 29:A805, 1988
Holoye PY, Raber MN, Jeffries DG: Phase I Study of didemnin B in Non-Small Cell Bronchogenic Carcinoma. Proc Am Assoc Cancer Res 30:1077, 1989
Lassus M, Scott D, Leyland-Jones B: Allergic Reactions (AR) associated with Cremophor (C) containing antineoplastics (ANP). Proc Am Soc Clin Oncol 4:268, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maroun, J., Stewart, D., Verma, S. et al. Phase I clinical study of didemnin B. Invest New Drugs 16, 51–56 (1998). https://doi.org/10.1023/A:1006099401417
Issue Date:
DOI: https://doi.org/10.1023/A:1006099401417